{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T05:17:12Z","timestamp":1735017432228,"version":"3.32.0"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction This study evaluates the impact of Parkinson disease (PD)\n                    medication in advanced PD on neuropsychological performance, psychiatric\n                    symptoms, impulsivity and the quality of life. In the 4-year period 27 patients\n                    with advanced PD, scheduled for deep brain stimulation (DBS) surgery (N=27, mean\n                    age: 58.9\u00b17.1, disease duration: 10.0 years\u00b14.2) were examined preoperatively.\n                    We hypothesized that a high dosage of PD medication or current use of dopamine\n                    agonists affect cognitive functioning and psychiatric wellbeing.<\/jats:p><jats:p>\n          Methods We performed two subgroup analyses with low versus high\n                    levodopa-equivalent Dosage (LED) medication and without versus with\n                    dopaminagonistic medication.<\/jats:p><jats:p>\n          Results The neuropsychological testing revealed significant differences in\n                    the verbal learn- and memory-test (VLMT) during the learning passage (U=36.500,\n                    Z=\u2212\u20092.475, p=0.012) and in the subtest of the semantic fluency of Regensburg\n                    verbal fluency test (RWT) (t(25)=\u2212\u20092.066, p=0.049) with better results for\n                    patients without dopaminagonistic medication. Pearson correlation analyses of\n                    LED in correlation with the clinical and cognitive dependent variables showed a\n                    significant higher PANSS total score in patients with higher LED medication\n                    (r=0.491, p=0.009). In addition, lower LED treatment was associated with\n                    significant higher scores in the impulsivity perseverance subtest (r=\u2212\u20090.509,\n                    p=0.008).<\/jats:p><jats:p>\n          Discussion In conclusion, we found lower LEDs to be correlated with a\n                    better perseverance in the impulsivity test and additional treatment with a\n                    dopamine agonist influenced some verbal learning tasks and the PANSS total score\n                    in patients with advanced PD. This should be considered prior to DBS\n                    surgery.<\/jats:p>","DOI":"10.1055\/a-2446-6877","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:00:16Z","timestamp":1732240816000},"page":"5-13","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive\n                    Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain\n                    Stimulation"],"prefix":"10.1055","volume":"58","author":[{"given":"Jan","family":"Haeckert","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Medical\n                    Faculty, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Roeh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Medical\n                    Faculty, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Karch","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Hospital Munich,\n                    LMU Munich, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Koeglsperger","sequence":"additional","affiliation":[{"name":"Department of Neurology, LMU University Hospital, LMU Munich, Munich,\n                    Germany"},{"name":"Department of Translational Brain Research, German Center for\n                    Neurodegenerative Diseases (DZNE), Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Medical\n                    Faculty, University of Augsburg, Augsburg, Germany"},{"name":"DZPG (German Center for Mental Health), partner site Munich\/Augsburg,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Papazova","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Medical\n                    Faculty, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"W Poewe","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A\n                    clinico-pathological study of 100 cases","volume":"55","author":"A J Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson\u2019s disease in the U.S.\n                    Npj Park Dis","volume":"6","author":"W Yang","year":"2020"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s disease with early motor complications","volume":"368","author":"WM M Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1212\/WNL.0b013e31829c5c86","article-title":"Evolution of mild cognitive impairment in Parkinson disease","volume":"81","author":"M Broeders","year":"2013","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"D Aarsland","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awh067","article-title":"The cognitive ability of an incident cohort of Parkinson\u2019s patients in the UK.\n                    The CamPaIGN study","volume":"127","author":"T Foltynie","year":"2004","journal-title":"Brain"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease\n                    cohort","volume":"130","author":"C H Williams-Gray","year":"2007","journal-title":"Brain"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for l-DOPA treatment\n                    in Parkinson\u2019s disease","volume":"30","author":"R Cools","year":"2006","journal-title":"Neurosci Biobehav Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1002\/mds.20963","article-title":"Deep brain stimulation: Neuropsychological and neuropsychiatric issues","volume":"21","author":"V Voon","year":"2006","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1017\/cjn.2016.35","article-title":"Eligibility criteria for deep brain stimulation in Parkinson\u2019s disease, tremor,\n                    and dystonia","volume":"43","author":"R P Munhoz","year":"2016","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2012.00066","article-title":"Deep brain stimulation and cognitive decline in Parkinson\u2019s disease: A clinical\n                    review","volume":"3","author":"J Massano","year":"2012","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1034\/j.1600-0447.2002.02229.x","article-title":"Major depressive disorder in Parkinson\u2019s disease: A register-based study","volume":"106","author":"F M Nilsson","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease \u2013 epidemiology, mechanisms and management","volume":"8","author":"D Aarsland","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1093\/brain\/awn214","article-title":"A multicentre study on suicide outcomes following subthalamic stimulation for\n                    Parkinson\u2019s disease","volume":"131","author":"V Voon","year":"2008","journal-title":"Brain"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease","volume":"362","author":"K A Follett","year":"2010","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40266-016-0416-8","article-title":"Psychosis in Parkinson disease: A review of etiology, phenomenology, and\n                    management","volume":"33","author":"N Samudra","year":"2016","journal-title":"Drugs Aging"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40263-017-0450-z","article-title":"Dopaminergic therapies for non-motor symptoms in Parkinson\u2019s disease","volume":"31","author":"E Schaeffer","year":"2017","journal-title":"CNS Drugs"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archpsyc.1997.01830140071013","article-title":"Auditory working memory and Wisconsin Card Sorting Test performance in\n                    schizophrenia","volume":"54","author":"J M Gold","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","article-title":"The Parkinson\u2019s Disease Questionnaire (PDQ-39): Development and validation of a\n                    Parkinson\u2019s disease summary index score","volume":"26","author":"C Jenkinson","year":"1997","journal-title":"Age Ageing"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"M Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","first-page":"709","article-title":"Geriatric depression scale","volume":"24","author":"J A Yesavage","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0191-8869(00)00064-7","article-title":"The five factor model and impulsivity: Using a structural model of personality\n                    to understand impulsivity","volume":"30","author":"S P Whiteside","year":"2001","journal-title":"Personal Individ Differ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease\n                    Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing\n                    results","volume":"23","author":"C G Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: An updated proposal including\n                    opicapone and safinamide","volume":"7","author":"S Schade","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease:\n                    Systematic review of LED reporting in PD","volume":"25","author":"C L Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1136\/jnnp.2006.111161","article-title":"The 39 item Parkinson\u2019s disease questionnaire (PDQ-39) revisited: Implications\n                    for evidence based medicine","volume":"78","author":"P Hagell","year":"2007","journal-title":"J Neurol Neurosurg Amp Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson\u2019s disease severity levels and MDS-Unified Parkinson\u2019s Disease Rating\n                    Scale","volume":"21","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1016\/j.neuropsychologia.2012.09.016","article-title":"Verbal fluency in Parkinson\u2019s disease patients on\/off dopamine medication","volume":"50","author":"E Herrera","year":"2012","journal-title":"Neuropsychologia"},{"key":"ref39","first-page":"13","article-title":"The effect of dopamine agonists on cognitive functions in non-demented\n                    early-mild Parkinson\u2019s disease patients","volume":"28","author":"L Brusa","year":"2013","journal-title":"Funct Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2017.01.013","article-title":"Personality in Parkinson\u2019s disease: Clinical, behavioural and cognitive\n                    correlates","volume":"374","author":"G Santangelo","year":"2017","journal-title":"J Neurol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/WNN.0b013e3181c12c63","article-title":"Cognitive and personality features in Parkinson disease: 2 sides of the same\n                    coin?","volume":"22","author":"C Volpato","year":"2009","journal-title":"Cogn Behav Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1093\/brain\/awp094","article-title":"Reward-learning and the novelty-seeking personality: A between- and\n                    within-subjects study of the effects of dopamine agonists on young Parkinson\u2019s\n                    patients","volume":"132","author":"N Bodi","year":"2009","journal-title":"Brain"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10654-015-0062-1","article-title":"Personality traits and the risk for Parkinson disease: A prospective study","volume":"31","author":"J Sieurin","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/01.wnl.0000184487.72289.f0","article-title":"Factors influencing susceptibility to compulsive dopaminergic drug use in\n                    Parkinson disease","volume":"65","author":"A H Evans","year":"2005","journal-title":"Neurology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson\u2019s disease: From dyskinesias to\n                    impulse control disorders","volume":"8","author":"V Voon","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S1353-8020(09)70794-1","article-title":"Impulse control disorders in Parkinson\u2019s disease: Prevalence and possible risk\n                    factors","volume":"15","author":"D Weintraub","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/hbm.22344","article-title":"Dopamine-agonists and impulsivity in Parkinson\u2019s disease: Impulsive choices vs.\n                    impulsive actions","volume":"35","author":"F Antonelli","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson\u2019s disease","volume":"289","author":"G F\u00e9nelon","year":"2010","journal-title":"J Neurol Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/jnnp.2007.124677","article-title":"Using the presence of visual hallucinations to differentiate Parkinson\u2019s disease\n                    from atypical parkinsonism","volume":"79","author":"D R Williams","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson\u2019s disease: A randomised,\n                    placebo controlled study with open follow up","volume":"75","author":"P Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jnnp-2012-304440","article-title":"Demographic and motor features associated with the occurrence of\n                    neuropsychiatric and sleep complications of Parkinson\u2019s disease","volume":"84","author":"R P Munhoz","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/mds.22589","article-title":"Neuropsychiatric symptoms in Parkinson\u2019s disease","volume":"24","author":"D Aarsland","year":"2009","journal-title":"Mov Disord"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1600-0404.2006.00579.x","article-title":"A systematic review of depression and mental illness preceding Parkinson\u2019s\n                    disease","volume":"113","author":"L Ishihara","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00702-021-02456-3","article-title":"Parkinson and depression: Review and outlook","volume":"129","author":"G Laux","year":"2022","journal-title":"J Neural Transm"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11585380-000000000-00000","article-title":"The role of dopamine agonists in the treatment of depression in patients with\n                    Parkinson\u2019s disease: A systematic review","volume":"71","author":"A F Leentjens","year":"2011","journal-title":"Drugs"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1037\/1082-989X.7.1.19","article-title":"On the practice of dichotomization of quantitative variables","volume":"7","author":"R C MacCallum","year":"2002","journal-title":"Psychol Methods"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2446-6877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T23:47:56Z","timestamp":1734997676000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2446-6877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":47,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,12,23]]},"published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2446-6877","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}